SOHO Brazil

 

SOHO Brazil 2022
25:36

SOHO Brazil 2022

SOHO Brazil 2022: Are All MZLs the Same? What Do We Know About Subtypes & Transformation?

FEATURING Izidore Lossos, Phillip Scheinberg
  • 24 views
  • August 31, 2022
27:08

SOHO Brazil 2022

Are We Curing Some Mantle Cell Lymphomas?

FEATURING Julio Chavez, Alvaro Alencar
  • 53 views
  • August 31, 2022
23:08

SOHO Brazil 2022

SOHO Brazil 2022 on Bispecifics in Follicular Lymphoma: A “Mini-Revolution”

FEATURING Julio Chavez, Alvaro Alencar
  • 12 views
  • August 31, 2022
24:15

SOHO Brazil 2022

SOHO Brazil 2022 on CPIs in Hodgkin Lymphoma: Recent Progress

FEATURING Philippe Armand, Alvaro Alencar
  • 56 views
  • August 31, 2022
24:28

SOHO Brazil 2022

SOHO Brazil 2022 on DLBCL: Finally Breaking the Back of R-CHOP?

FEATURING Craig Moskowitz, Alvaro Alencar
  • 80 views
  • August 31, 2022
23:04

SOHO Brazil 2022

SOHO Brazil 2022 on 1st Relapse in DLBCL: Induction Chemo & Autotransplant. Wait, Not So Fast…

FEATURING Michael Bishop, Phillip Scheinberg
  • 6 views
  • August 31, 2022
26:04

SOHO Brazil 2022

SOHO Brazil 2022 on Targeted Therapy in Indolent Lymphomas: The Role of PI3K & Other Inhibitors

FEATURING Izidore Lossos, Phillip Scheinberg
  • 34 views
  • August 31, 2022
32:17

SOHO Brazil 2022

SOHO Brazil 2022 on Waldenstrom’s Macroglobulinemia: The More Difficult Patient

FEATURING Steven Treon, Phillip Scheinberg
  • 68 views
  • August 31, 2022
27:03

SOHO Brazil 2022

SOHO Brazil 2022: Who Is a Candidate for CAR-T in DLBCL? The Window of Opportunity That Cannot Be Missed & Opportunities for the Future

FEATURING Michael Bishop, Alvaro Alencar, Phillip Scheinberg
  • 9 views
  • August 31, 2022
36:30

SOHO Brazil 2022

SOHO Brazil 2022 Discussion: What Are the Options in Primary CNS Lymphoma?

FEATURING James Rubenstein, Alvaro Alencar
  • 31 views
  • August 31, 2022
23:00

SOHO Brazil 2022

SOHO Brazil 2022 Discussion on MM: Will Sequencing Be Important With Newer Therapies?

FEATURING Michael Bishop, Neha Korde, Elisabet Manasanch, Phillip Scheinberg
  • 37 views
  • August 31, 2022
26:42

SOHO Brazil 2022

SOHO Brazil 2022: When Low-Risk MDS Behaves Badly

FEATURING Amer Zeidan, Phillip Scheinberg
  • 3 views
  • August 31, 2022
15:29

SOHO Brazil 2022

SOHO Brazil 2022 on CAR-T in Refractory MM: When Is the Precise Moment to Indicate - Past the Timing, Opportunity Lost

FEATURING Michael Bishop, Phillip Scheinberg
  • 134 views
  • August 31, 2022
16:24

SOHO Brazil 2022

SOHO Brazil 2022 Latest News on Third Generation Imune Modulating Agents & Proteasome Inhibitors in MM: Combinations

FEATURING Elisabet Manasanch, Phillip Scheinberg
  • 15 views
  • August 31, 2022
29:02

SOHO Brazil 2022

SOHO Brazil 2022: My Low-Risk MDS Patient With Ring Sideroblasts Is Losing Response to Erythropoietin - What to do?

FEATURING Hetty Carraway, Phillip Scheinberg
  • 35 views
  • August 31, 2022
20:09

SOHO Brazil 2022

SOHO Brazil 2022: How Is the Great Barrier of Highly-Resistant Myeloid Neoplasms Being Overcome

FEATURING Amer Zeidan, Phillip Scheinberg
  • 3 views
  • August 31, 2022
27:44

SOHO Brazil 2022

SOHO Brazil 2022 on MDS: Get to Know the IPSS-M & Other Molecularly-Integrated Risk Scores - Why It's Important and How It's Applied

FEATURING Mikkael Sekeres, Phillip Scheinberg
  • 38 views
  • August 31, 2022
29:49

SOHO Brazil 2022

SOHO Brazil 2022: Bringing AML Approaches to High-Risk MDS - Is It Working?

FEATURING Amer Zeidan, Phillip Scheinberg
  • 53 views
  • August 31, 2022
23:10

SOHO Brazil 2022

SOHO Brazil 2022: All You Need to Know (Until Now) About Targeted Therapy in AML. Summary of All Summaries

FEATURING Keith Pratz, Phillip Scheinberg
  • 77 views
  • August 31, 2022
32:48

SOHO Brazil 2022

SOHO Brazil 2022 on Refractory ALL: What Is the Precise Time to Indicate CAR-T? The Golden Window That Cannot Be Missed

FEATURING Michael Bishop, Phillip Scheinberg
  • 4 views
  • August 30, 2022
16:45

SOHO Brazil 2022

SOHO Brazil 2022 on CLL: The PI3K Inhibitors, the "Not-So-New Kid on the Block"

FEATURING Nitin Jain, Phillip Scheinberg
  • 5 views
  • August 30, 2022
20:09

SOHO Brazil 2022

SOHO Brazil 2022 on CLL: The BTK Inhibitors That Continue to “Heat-Up” the Class

FEATURING Nitin Jain, Phillip Scheinberg
  • 16 views
  • August 30, 2022
22:54

SOHO Brazil 2022

SOHO Brazil 2022 on Ph+ ALL: Is the Combination With TKIs Curing Patients?

FEATURING Josep-Maria Ribera, Phillip Scheinberg
  • 38 views
  • August 30, 2022
20:04

SOHO Brazil 2022

SOHO Brazil 2022 on High-Risk AML: Is Conventional Chemo Still the Best?

FEATURING Daniel Pollyea, Phillip Scheinberg
  • 7 views
  • August 30, 2022
20:23

SOHO Brazil 2022

SOHO Brazil 2022 on Doublets & Triplets With Venetoclax in AML: What Is the Most Recent in Practice and Research?

FEATURING Daniel Pollyea, Phillip Scheinberg
  • 9 views
  • August 30, 2022
26:48

SOHO Brazil 2022

SOHO Brazil 2022 on CLL: Do BTKi + BCL2 Inhibitors Need a Partner?

FEATURING Nitin Jain, Phillip Scheinberg
  • 8 views
  • August 30, 2022
25:29

SOHO Brazil 2022

SOHO Brazil 2022: Can Someone Be Destined to Develop AML? Understanding Germline Mutations

FEATURING Lucy Godley, Phillip Scheinberg
  • 15 views
  • August 30, 2022
  • 1